Clinical study of intrapleural injection of ropivacaine with different concentrations for post thoracoscopic lobectomy pain and related discomfort

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065184

Enrollment

Unknown

Registered

2022-10-31

Start date

2022-11-01

Completion date

Unknown

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative analgesia

Interventions

A:0.5% Ropivacaine

B:0.25% Ropivacaine

C:0.125% Ropivacaine

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Age over 18 years old; scheduled for thoracoscopic lobectomy; ASA class ?-?; cardiac function class ?-?.

Exclusion criteria

Exclusion criteria: History of chronic pain; Alcohol and opioid dependence; Severe dysfunction of heart, liver and kidney ; Allergic to amide local anesthetics; Cognitive dysfunction; conversion to thoracotomy during operation,. No need for indwelling closed thoracic drainage tube after operation, and transfer to ICU after operation.

Design outcomes

Primary

Measure	Time frame
VAS score;SpO2;	—

Secondary

Measure	Time frame
heart rat;blood pressure;postoperative complications;	—

Countries

China

Contacts

Public ContactHao Yonggang

The First Affiliated Hospital of Chongqing Medical University

5913988@qq.com13527411531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026